What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperative chemotherapy
Annals of Surgical Oncology,

Narita M et al. – This study provides a cutoff future liver remnant (FLR) ratio for safe postoperative outcome after major hepatectomy in colorectal liver metastases (CLM) patients receiving six or more cycles of preoperative chemotherapy.

Methods
  • Between January 2000 and August 2010, a total of 101 consecutive patients with CLM underwent major hepatectomy after preoperative chemotherapy (≥6 cycles of oxaliplatin or irinotecan regimen with or without targeted therapies).
  • The FLR ratio was calculated by two formulas: actual FLR (aFLR) ratio, and standardized FLR (sFLR) ratio.
  • Predictors of postoperative overall morbidity, sepsis, and liver failure were identified by univariate and multivariate analyses.

Results
  • Fifty–eight patients (57.4%) had 95 postoperative complications.
  • Sepsis and postoperative liver failure occurred in 23 (22.8%) and 16 patients (15.8%), respectively.
  • On univariate analysis, small aFLR ratio was significantly associated with all complications, and sFLR ratio was associated with sepsis and liver failure.
  • In receiver–operating characteristic analysis, the cutoff of aFLR ratio in predicting overall morbidity, sepsis, and liver failure was 44.8, 43.1, and 37.7%, respectively, and that of sFLR ratio in predicting sepsis and liver failure was 43.6 and 48.5%, respectively.
  • On multivariate analysis, these aFLR and sFLR ratio cutoffs were independent predictors of all complications and of sepsis and liver failure, respectively.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Gastroenterology Articles

1 Fungal microbiota and digestive diseases Alimentary Pharmacology and Therapeutics, March 5, 2014    Review Article

2 Accuracy of rapid fecal calprotectin test in monitoring inflammatory bowel diseases under treatment with TNFα antagonists Digestive Diseases and Sciences, December 9, 2014    Clinical Article

3 Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterology & Motility, December 3, 2014    Review Article

4 Crohn's disease management after intestinal resection: a randomised trial The Lancet, January 7, 2015    Evidence Based Medicine    Clinical Article

5 Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial Gut, January 14, 2015    Clinical Article

6 Effect of a low-flatulogenic diet in patients with flatulence and functional digestive symptoms Neurogastroenterology & Motility, February 25, 2014    Clinical Article
Exclusive Author Commentary

7 Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial Neurogastroenterology & Motility, February 10, 2014    Clinical Article

8 Risk of cancer in patients with inflammatory bowel diseases: A nationwide population-based cohort study with 30 years of follow-up evaluation Clinical Gastroenterology and Hepatology , January 17, 2014    Clinical Article

9 Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: A meta-analysis Clinical Gastroenterology and Hepatology , September 26, 2014    Evidence Based Medicine

10 Probiotics and antibiotics in IBD Digestive Diseases, January 23, 2015    Clinical Article

11 Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease Alimentary Pharmacology and Therapeutics, February 28, 2014    Clinical Article

12 Long-term outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical remission Clinical Gastroenterology and Hepatology , December 5, 2014    Clinical Article

13 Iron treatment and inflammatory bowel disease Journal of Crohn's and Colitis, February 11, 2014    Clinical Article

14 Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease Gastroenterology, April 2, 2014    Clinical Article

15 The dirty side of soap UC San Diego Health System, November 19, 2014

16 Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clinical Gastroenterology and Hepatology , September 25, 2014    Clinical Article

17 Diet and inflammatory bowel disease: review of patient-targeted recommendations Clinical Gastroenterology and Hepatology , October 10, 2014    Review Article

18 Use of antibiotics in patients with Crohn's disease: A systematic review and meta-analysis Journal of Digestive Diseases, December 4, 2014    Evidence Based Medicine    Review Article

19 Why, when and how to de-escalate therapy in inflammatory bowel diseases Alimentary Pharmacology and Therapeutics, July 2, 2014    Review Article

20 Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: A diagnostic meta-analysis Full Text BMC Gastroenterology, July 14, 2014    Free full text    Evidence Based Medicine

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List